ETC-1002, a novel agent in development by Esperion Therapeutics, lowered LDL levels by nearly 43% in patients with type 2 diabetes and hypercholesterolemia, according to phase 2 study results.
The compound works by activating adenosine monophosphate-activated protein kinase and inhibiting adenosine triphosphate-citrate lyase, according to the study background.
Full Story »
Personalize your page!
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.